Physiologically‐based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors

por Ueno, Takashi, Miyajima, Yukiko, Landry, Ishani, Lalovic, Bojan, Schuck, Edgar
Publicado 2021

Population Pharmacokinetics and Exposure‐Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects Wit...

por Lalovic, Bojan, Majid, Oneeb, Aluri, Jagadeesh, Landry, Ishani, Moline, Margaret, Hussein, Ziad
Publicado 2020

Dexmedetomidine Pharmacokinetics in Neonates with Hypoxic-Ischemic Encephalopathy Receiving Hypothermia

por McAdams, Ryan M., Pak, Daniel, Lalovic, Bojan, Phillips, Brian, Shen, Danny D.
Publicado 2020

Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single‐Dose and Multiple‐Ascending‐Dose Phase 1 Studies in Healthy...

por Landry, Ishani, Nakai, Kenya, Ferry, Jim, Aluri, Jagadeesh, Hall, Nancy, Lalovic, Bojan, Moline, Margaret L.
Publicado 2020

Evaluation of the CYP3A and CYP2B6 Drug‐Drug Interaction Potential of Lemborexant

por Landry, Ishani, Aluri, Jagadeesh, Nakai, Kenya, Hall, Nancy, Miyajima, Yukiko, Ueno, Takashi, Dayal, Satish, Filippov, Gleb, Lalovic, Bojan, Moline, Margaret, Reyderman, Larisa
Publicado 2021